Search

Your search keyword '"Zatta I"' showing total 3 results
Start Over Author "Zatta I" Publisher wiley-blackwell
3 results on '"Zatta I"'

2. Exploring the prognostic role of complex karyotype in chronic lymphocytic leukaemia patients treated with venetoclax-based regimens.

Author

Serafin A, Cellini A, Cavarretta CA, Ruocco V, Angotzi F, Zatta I, Frezzato F, Bonaldi L, Martines A, Pravato S, Piazza F, Trentin L, and Visentin A

Subjects
Humans, Female, Male, Aged, Middle Aged, Prognosis, Retrospective Studies, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Aged, 80 and over, Karyotype, Adult, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Leukemia, Lymphocytic, Chronic, B-Cell genetics, Leukemia, Lymphocytic, Chronic, B-Cell mortality, Bridged Bicyclo Compounds, Heterocyclic therapeutic use, Bridged Bicyclo Compounds, Heterocyclic administration & dosage, Sulfonamides therapeutic use, Sulfonamides administration & dosage
Abstract

Although the unfavourable prognostic role of complex karyotype (CK) in chronic lymphocytic leukaemia (CLL) patients treated with chemoimmunotherapy has been clarified, its impact on the outcome of patients being treated with novel targeted agents, and especially with venetoclax-based regimens, remains to be resolved. In fact, only few studies, utilizing data derived from clinical trials (e.g. MURANO, CLL14, GAIA-CLL13), specifically focus on this topic while real-word evidence is missing. In our real-life retrospective study conducted on 61 patients with CLL and treated with venetoclax-based regimens in any therapeutic line, we documented a remarkable lower progression-free survival in patients harbouring both CK and high CK, while overall response rate (including complete remissions and partial remissions) and overall survival are not affected by CK in our population., (© 2024 British Society for Haematology and John Wiley & Sons Ltd.)

Published
2024
Full Text
View/download PDF

3. Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study.

Author

Visentin A, Mauro FR, Scarfò L, Gentile M, Farina L, Reda G, Ferrarini I, Proietti G, Derenzini E, Cibien F, Vitale C, Sanna A, Pietrasanta D, Marchetti M, Murru R, Rigolin GM, Sportoletti P, Trimarco V, Cavarretta CA, Angotzi F, Cellini A, Ruocco V, Zatta I, Laurenti L, Molica S, Coscia M, Ghia P, Foà R, Cuneo A, and Trentin L

Subjects
Humans, Bridged Bicyclo Compounds, Heterocyclic therapeutic use, Sulfonamides therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Tumor Suppressor Protein p53 genetics, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Leukemia, Lymphocytic, Chronic, B-Cell genetics, Antineoplastic Agents therapeutic use
Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results